This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
LifeSpan Biosciences
product type :
protein
product name :
Human BCL2L11 / BIM Protein (Recombinant His) - LS-G1887
catalog :
LS-G1887
product information
ProteinId :
1887
CatalogNumber :
LS-G1887
Product Name :
Human BCL2L11 / BIM Protein (Recombinant His) - LS-G1887
PresentationDesc :
20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 2 M urea, 20% glycerol, 5 mM DTT
ProteinTag :
His
ProteinType :
Recombinant
ProteinSpecies :
Human
ProteinSourceSpecies :
E. coli
RecommendedStorage :
Short term: store at 2°C to 8°C for up to 1 week. Long term: aliquot and store at -20°C to -80°C. Avoid freeze-thaw cycles.
Purification :
Greater than 80% by SDS-PAGE
Gene :
BCL2L11 / BIM
StandardGeneSymbol :
BCL2L11
gene family :
Apoptosis
Synonyms :
BCL2L11, BIM-alpha6, BIM-beta7, Bcl-2-like protein 11, BIM-beta6, BimL, BimS, Bcl-2 interacting protein Bim, BimEL, BAM, Bcl2-L-11, BIM, BOD
SalesRegion :
Worldwide
company information
LifeSpan Biosciences
2401 Fourth Avenue, Suite 900
Seattle, WA 98121
Seattle, WA 98121
CustomerSupport@lsbio.com
https://www.lsbio.com1-206-464-1554
headquarters: USA
Since 1995, LifeSpan has been the industry leader in molecular pathology, specializing in the localization of proteins in normal and diseased tissues, both human and non-human. We offer more than 74,000 antibodies, custom designed immunohistochemistry (IHC) studies, immediately available human tissue IHC profiles for more than 500 proteins, and histology and pathology services. Our bank of 2 million specimens is available to support our customers' contract research studies and contains frozen and formalin-fixed (FFPE) normal and diseased tissues. Our contract services are comprehensive; they include study design, antibody sourcing and characterization, tissue sourcing and validation, immunolabeling, trouble shooting, and interpretation of the results by a LifeSpan pathologist.
questions and comments